P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR METASTATIC BRCA EC

P3 紫杉醇贝伐珠单抗作为第一线治疗局部复发性转移性 BRCA EC

• 批准号: 7625857
• 负责人: Witold B. Rybka
• 金额: $ 0.22万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625857
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Paclitaxel; Patients; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; bevacizumab; malignant breast neoplasm

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the effects of paclitaxel in combination with bevacizumab or paclitaxel alone in patients with breast cancer that has spread or reocurred.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是比较紫杉醇联合贝伐单抗或紫杉醇单药治疗已扩散或复发的乳腺癌患者的效果。